查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1942509

2026年全球癌症診斷市場報告

Cancer Diagnostics Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

がん診断市場の規模は近年急速に拡大しております。2025年の255億米ドルから2026年には285億8,000万米ドルへと、CAGR12.1％で成長が見込まれております。過去数年間の成長は、世界のがん罹患率の上昇、腫瘍学調査への投資増加、病院診断インフラの拡充、画像診断に基づくがん検出法の普及拡大、檢查室の自動化進歩などが要因とされています。

がん診断市場規模は今後数年間で急速な成長が見込まれております。2030年には446億9,000万米ドルに達し、CAGRは11.8％となる見込みです。予測期間における成長は、個別化がん治療への需要増加、次世代定序診断の普及拡大、人口全体を対象としたがん検診プログラムの拡充、AIを活用した腫瘍診断への投資拡大、多がん検出検査における継続的な技術革新などが要因となります。予測期間における主な動向としては、分子診断およびコンパニオン診断の採用拡大、がん検出におけるAIの統合増加、バイオマーカーベース検査の利用拡大、ハイスループット診断プラットフォームの拡充、早期がん検診への注力強化などが挙げられます。

預計未來幾年，不斷成長的醫療費用支出將推動癌症診斷市場的成長。醫療費用支出是指政府、企業和個人用於醫療程序、住院治療、藥物和公共衛生措施的總資金。醫療費用支出需求的成長主要是由於需要長期且昂貴治療的慢性疾病日益普遍。不斷成長的醫療保健醫療費用支出透過促進先進篩檢技術的應用和擴大早期檢測服務的覆蓋範圍，為癌症診斷提供了支持。對現代化設備和專業檢查室的投資提高了診斷準確性，實現了及時干預，並改善了患者的治療效果。例如，根據英國國家統計局2024年5月發布的數據，2023年醫療保健總支出名目值將增加5.6%，比2022年增加0.9%。因此，不斷成長的醫療費用支出正在推動癌症診斷市場的成長。

肺癌發生率的不斷上升也是推動癌症診斷市場發展的關鍵因素。肺癌是一種異常細胞在肺組織中不受控制地生長，形成腫瘤並轉移到身體其他部位的疾病。癌症診斷設備對於肺癌的檢測、診斷和後續觀察至關重要，在幫助醫護人員確定癌症的存在、類型和分期以及製定治療方案方面發揮關鍵作用。例如，美國臨床腫瘤學會（ASCO）在2023年3月估計，2023年美國將確診238,340例肺癌病例，高於2022年的236,000例。因此，肺癌發生率的上升正在推動癌症診斷市場的擴張。

目錄

第1章執行摘要

第2章 市場特徵

  • 市場定義和範圍
  • 市場區隔
  • 主要產品和服務概述
  • 全球癌症診斷市場：吸引力評分及分析
  • 成長潛力分析、競爭評估、策略契合度評估、風險狀況評估

第3章 市場供應鏈分析

  • 供應鏈與生態系概述
  • 主要原料、資源和供應商清單
  • 主要經銷商和通路合作夥伴名單
  • 主要最終用戶列表

第4章 全球市場趨勢與策略

  • 關鍵技術和未來趨勢
    • 人工智慧（AI）和自主人工智慧
    • 生物技術、基因組學和精準醫學
    • 數位化、雲端運算、巨量資料、網路安全
    • 工業4.0和智慧製造
    • 物聯網、智慧基礎設施和互聯生態系統
  • 主要趨勢
    • 分子診斷和伴隨診斷的廣泛應用
    • 人工智慧在癌症檢測的應用進展
    • 擴大基於生物標記的檢測應用
    • 擴展高通量診斷平台
    • 人們越來越關注癌症早期篩檢

第5章 終端用戶產業市場分析

  • 醫院
  • 診斷檢查室
  • 癌症研究所
  • 專業腫瘤中心
  • 學術醫療機構

第6章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅的影響、關稅戰和貿易保護主義對供應鏈的影響，以及新冠疫情對市場的影響

第7章 全球策略分析架構、目前市場規模、市場對比及成長率分析

  • 全球癌症診斷市場：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 全球癌症診斷市場規模、比較及成長率分析
  • 全球癌症診斷市場表現：規模與成長，2020-2025年
  • 全球癌症診斷市場預測：規模與成長，2025-2030年，2035年預測

第8章 全球潛在市場總量（TAM）

第9章 市場細分

  • 依產品
  • 伴隨診斷、分子診斷
  • 透過方法
  • 切片檢查、內視鏡檢查、腫瘤生物標記檢測、影像診斷
  • 透過使用
  • 子宮頸癌、乳癌、肝癌、血癌、腎臟癌、結腸癌、胰臟癌、卵巢癌、黑色素瘤及其他適應症
  • 最終用戶
  • 癌症研究機構、診斷檢查室、醫院和其他最終用戶
  • 按類型細分：伴隨診斷
  • 基於生物標記的伴隨診斷、基於基因檢測的伴隨診斷、基於免疫組織化學的伴隨診斷、基於PCR的伴隨診斷和其他伴隨診斷
  • 按類型細分：分子診斷
  • 聚合酵素鏈鎖反應（PCR）診斷、次世代定序（NGS）診斷、原位雜合反應診斷、基於微陣列的診斷、DNA或RNA萃取試劑盒以及其他分子診斷

第10章 區域與國家分析

  • 全球癌症診斷市場：依地區、績效及預測分類，2020-2025年、2025-2030年預測、2035年預測
  • 全球癌症診斷市場：依國家、績效及預測分類，2020-2025年、2025-2030年預測、2035年預測

第11章 亞太市場

第12章：中國市場

第13章 印度市場

第14章 日本市場

第15章：澳洲市場

第16章 印尼市場

第17章 韓國市場

第18章 孟加拉國市場

第19章 泰國市場

第20章 越南市場

第21章 馬來西亞市場

第22章 新加坡市場

第23章：菲律賓市場

第24章 香港市場

第25章：紐西蘭市場

第26章 台灣市場

第27章 東南亞市場

第28章 西歐市場

第29章英國市場

第30章：德國市場

第31章：法國市場

第32章：義大利市場

第33章：西班牙市場

第34章：奧地利市場

第35章：比利時市場

第36章：丹麥市場

第37章 芬蘭市場

第38章：愛爾蘭市場

第39章：荷蘭市場

第40章：挪威市場

第41章：葡萄牙市場

第42章：瑞典市場

第42章 瑞士市場

第43章 東歐市場

第44章：俄羅斯市場

第45章：捷克市場

第46章：波蘭市場

第47章：羅馬尼亞市場

第48章：烏克蘭市場

第49章 北美市場

第50章：美國市場

第51章 加拿大市場

第52章：墨西哥市場

第53章 南美洲市場

第54章：巴西市場

第55章 智利市場

第56章：阿根廷市場

第57章：哥倫比亞市場

第58章 秘魯市場

第59章 中東市場

第60章：沙烏地阿拉伯市場

第61章：以色列市場

第62章 伊朗市場

第63章 土耳其市場

第64章：阿拉伯聯合大公國市場

第65章：非洲市場

第66章 埃及市場

第67章：奈及利亞市場

第68章 南非市場

第69章 市場監理與投資環境

第70章：競爭格局與公司概況

  • 癌症診斷市場：競爭格局與市場佔有率（2024 年）
  • 癌症診斷市場：公司估值矩陣
  • 癌症診斷市場：公司概況
    • Abbott Laboratories
    • Becton Dickinson and Company
    • Hologic
    • GE Healthcare Ltd.
    • Thermo Fisher Scientific

第71章：其他領先和創新企業

  • Siemens Healthcare GmbH, Biogenex Laboratories, Veracyte, PathAI, Bio-Rad Laboratories, BioChain, DiagnoCure, Illumina, Myriad Genetics, CompanionDx, Epic Sciences, Genomic Health, Affymetrix, Agilent Technologies, Adaptive Biotechnologies

第72章：全球市場競爭基準分析與儀錶板

第73章：重大併購

第74章：高潛力市場國家、細分市場與策略

  • 2030年癌症診斷市場：提供新機會的國家
  • 2030年癌症診斷市場：新興細分市場機會
  • 2030年癌症診斷市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第75章附錄

簡介目錄
Product Code: ME3MCDIA04_G26Q1

Cancer diagnostics involves the processes, tests, and technologies used to detect the presence of cancer in individuals. This area includes various methods aimed at identifying, staging, and characterizing cancer, enabling timely and effective treatment.

The primary offerings within the cancer diagnostics sector include companion diagnostics and molecular diagnostics. Molecular diagnostics involve laboratory procedures to detect particular proteins, genes, or molecules indicating the presence of cancer. Diagnostic methods in cancer assessments encompass biopsies, endoscopies, tumor biomarker tests, and imaging. These diagnostic tools cater to various applications, including cervical cancer, breast cancer, liver cancer, blood cancer, kidney cancer, colorectal cancer, pancreatic cancer, ovarian cancer, melanoma, and others. They are utilized by diverse end-users like cancer research institutes, diagnostic laboratories, hospitals, and related entities.

Tariffs are influencing the cancer diagnostics market by increasing costs of imported sequencing platforms, imaging systems, reagents, consumables, and laboratory automation equipment. Hospitals, diagnostic laboratories, and research institutes in North America and Europe are most affected due to heavy reliance on imported diagnostic technologies, while Asia-Pacific faces higher procurement costs for advanced testing platforms. These tariffs are raising testing costs and slowing laboratory expansion plans. At the same time, they are encouraging regional manufacturing of diagnostic kits, localized reagent production, and increased focus on cost-efficient diagnostic innovation.

The cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides cancer diagnostics market statistics, including cancer diagnostics industry global market size, regional shares, competitors with a cancer diagnostics market share, detailed cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the cancer diagnostics industry. This cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer diagnostics market size has grown rapidly in recent years. It will grow from $25.5 billion in 2025 to $28.58 billion in 2026 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to rising global cancer prevalence, increased investments in oncology research, expansion of hospital diagnostic infrastructure, growing adoption of imaging-based cancer detection, improvements in laboratory automation.

The cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $44.69 billion in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to increasing demand for personalized cancer therapies, rising adoption of next-generation sequencing diagnostics, expansion of population-wide cancer screening programs, growing investments in AI-enabled oncology diagnostics, continuous innovation in multi-cancer detection tests. Major trends in the forecast period include increasing adoption of molecular and companion diagnostics, rising integration of ai in cancer detection, growing use of biomarker-based testing, expansion of high-throughput diagnostic platforms, enhanced focus on early cancer screening.

Rising healthcare expenditure is expected to drive growth in the cancer diagnostics market in the coming years. Healthcare expenditure encompasses the total financial resources allocated to medical treatments, hospital care, medications, and public health initiatives by governments, businesses, and individuals. The growing demand for healthcare spending is largely driven by the increasing prevalence of chronic diseases, which require long-term and often costly care. Higher healthcare expenditure supports cancer diagnostics by enabling the adoption of advanced screening technologies and expanding access to early detection services. Investments in modern equipment and specialized laboratories enhance diagnostic accuracy, facilitate timely intervention, and improve patient outcomes. For example, in May 2024, the UK Office for National Statistics reported that total healthcare expenditure increased by 5.6% in nominal terms in 2023, representing a 0.9% rise compared to 2022. Therefore, rising healthcare expenditure is fueling the growth of the cancer diagnostics market.

The increasing incidence of lung cancer is another key factor driving the cancer diagnostics market. Lung cancer originates in the lung tissues, where abnormal cells grow uncontrollably, forming tumors that may spread to other parts of the body. Cancer diagnostic devices are essential for detecting, diagnosing, and monitoring lung cancer, helping healthcare professionals determine its presence, type, stage, and guide treatment decisions. For instance, in March 2023, the American Society of Clinical Oncology (ASCO), a US-based organization, estimated that 238,340 people in the United States would be diagnosed with lung cancer in 2023, up from 236,000 cases in 2022. Therefore, the rising incidence of lung cancer is contributing to the expansion of the cancer diagnostics market.

Major companies operating in the cancer diagnostics market are focusing on artificial intelligence (AI)-driven innovations to improve diagnostic precision and efficiency. AI-based tools analyze tissue samples and clinical data to aid pathologists in identifying cancerous and non-cancerous regions. For example, in March 2023, Qritive, a Singapore-based developer of AI-powered diagnostic solutions, launched QAi Prostate. This advanced AI-powered tool assists in prostate cancer diagnosis by using machine learning algorithms to accurately detect and classify malignant and benign areas in prostate tissue samples, supporting pathologists in making informed diagnostic and treatment decisions.

Major companies operating in the cancer diagnostics market are Abbott Laboratories, Becton Dickinson and Company, Hologic, GE Healthcare Ltd., Thermo Fisher Scientific, Siemens Healthcare GmbH, Biogenex Laboratories, Veracyte, PathAI, Bio-Rad Laboratories, BioChain, DiagnoCure, Illumina, Myriad Genetics, CompanionDx, Epic Sciences, Genomic Health, Affymetrix, Agilent Technologies, Adaptive Biotechnologies, Biocartis, Biocept, Cancer Genetics Inc., Caris Life Sciences, Cepheid, Epigenomics AG, Exact Sciences, Foundation Medicine, GenMark Diagnostics, Guardant Health, HalioDX, Invitae Corporation, NanoString Technologies, Natera, NeoGenomics, Oncura Inc., PerkinElmer, Personal Genome Diagnostics, Qiagen, Roche Diagnostics

North America was the largest region in the cancer diagnostics market in 2025. Asia-Pacific was the second-largest region in the global cancer diagnostics market. The regions covered in the cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cancer diagnostics market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.

The cancer diagnostics market consists of sales of pathology-based instruments (slide staining systems, tissue processing systems, cell processors, PCR instruments, NGS instruments, and other pathology-based instruments), imaging Instruments (CT systems, ultrasound systems, MRI systems, mammography systems, and nuclear imaging systems) and biopsy instruments that are used for the diagnosis of cancer. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer Diagnostics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Products: Companion Diagnostics; Molecular Diagnostics
  • 2) By Method: Biopsy; Endoscopy; Tumor Biomarker Tests; Imaging
  • 3) By Application: Cervical Cancer; Breast Cancer; Liver Cancer; Blood Cancer; Kidney Cancer; Colorectal Cancer; Pancreatic Cancer; Ovarian Cancer; Melanoma; Other Applications
  • 4) By End-User: Cancer Research Institutes; Diagnostic Laboratories; Hospitals; Other End Users
  • Subsegments:
  • 1) By Companion Diagnostics: Biomarker-Based Companion Diagnostics; Genetic Testing-Based Companion Diagnostics; Immunohistochemistry-Based Companion Diagnostics; PCR-Based Companion Diagnostics; Other Companion Diagnostics;
  • 2) By Molecular Diagnostics: Polymerase Chain Reaction (PCR) Diagnostics; Next-Generation Sequencing (NGS) Diagnostics; In Situ Hybridization Diagnostics; Microarray-Based Diagnostics; DNA Or RNA Extraction Kits; Other Molecular Diagnostics
  • Companies Mentioned: Abbott Laboratories; Becton Dickinson and Company; Hologic; GE Healthcare Ltd.; Thermo Fisher Scientific; Siemens Healthcare GmbH; Biogenex Laboratories; Veracyte; PathAI; Bio-Rad Laboratories; BioChain; DiagnoCure; Illumina; Myriad Genetics; CompanionDx; Epic Sciences; Genomic Health; Affymetrix; Agilent Technologies; Adaptive Biotechnologies; Biocartis; Biocept; Cancer Genetics Inc.; Caris Life Sciences; Cepheid; Epigenomics AG; Exact Sciences; Foundation Medicine; GenMark Diagnostics; Guardant Health; HalioDX; Invitae Corporation; NanoString Technologies; Natera; NeoGenomics; Oncura Inc.; PerkinElmer; Personal Genome Diagnostics; Qiagen; Roche Diagnostics
  • Countries: China; India; Japan; Australia; Indonesia; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; Taiwan; New Zealand; UK; Germany; France; Italy; Spain; Austria; Belgium; Denmark; Finland; Ireland; Netherlands; Norway; Portugal; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Cancer Diagnostics Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Cancer Diagnostics Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Cancer Diagnostics Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Cancer Diagnostics Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Artificial Intelligence & Autonomous Intelligence
    • 4.1.2 Biotechnology, Genomics & Precision Medicine
    • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.4 Industry 4.0 & Intelligent Manufacturing
    • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.2. Major Trends
    • 4.2.1 Increasing Adoption Of Molecular And Companion Diagnostics
    • 4.2.2 Rising Integration Of Ai In Cancer Detection
    • 4.2.3 Growing Use Of Biomarker-Based Testing
    • 4.2.4 Expansion Of High-Throughput Diagnostic Platforms
    • 4.2.5 Enhanced Focus On Early Cancer Screening

5. Cancer Diagnostics Market Analysis Of End Use Industries

  • 5.1 Hospitals
  • 5.2 Diagnostic Laboratories
  • 5.3 Cancer Research Institutes
  • 5.4 Specialty Oncology Centers
  • 5.5 Academic Medical Institutions

6. Cancer Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Cancer Diagnostics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Cancer Diagnostics Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Cancer Diagnostics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Cancer Diagnostics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Cancer Diagnostics Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Cancer Diagnostics Market Segmentation

  • 9.1. Global Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Companion Diagnostics, Molecular Diagnostics
  • 9.2. Global Cancer Diagnostics Market, Segmentation By Method, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Biopsy, Endoscopy, Tumor Biomarker Tests, Imaging
  • 9.3. Global Cancer Diagnostics Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Cervical Cancer, Breast Cancer, Liver Cancer, Blood Cancer, Kidney Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Melanoma, Other Applications
  • 9.4. Global Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Other End Users
  • 9.5. Global Cancer Diagnostics Market, Sub-Segmentation Of Companion Diagnostics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Biomarker-Based Companion Diagnostics, Genetic Testing-Based Companion Diagnostics, Immunohistochemistry-Based Companion Diagnostics, PCR-Based Companion Diagnostics, Other Companion Diagnostics
  • 9.6. Global Cancer Diagnostics Market, Sub-Segmentation Of Molecular Diagnostics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Polymerase Chain Reaction (PCR) Diagnostics, Next-Generation Sequencing (NGS) Diagnostics, In Situ Hybridization Diagnostics, Microarray-Based Diagnostics, DNA Or RNA Extraction Kits, Other Molecular Diagnostics

10. Cancer Diagnostics Market Regional And Country Analysis

  • 10.1. Global Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Cancer Diagnostics Market

  • 11.1. Asia-Pacific Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Cancer Diagnostics Market

  • 12.1. China Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Cancer Diagnostics Market

  • 13.1. India Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Cancer Diagnostics Market

  • 14.1. Japan Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Cancer Diagnostics Market

  • 15.1. Australia Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Cancer Diagnostics Market

  • 16.1. Indonesia Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Cancer Diagnostics Market

  • 17.1. South Korea Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Bangladesh Cancer Diagnostics Market

  • 18.1. Bangladesh Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. Thailand Cancer Diagnostics Market

  • 19.1. Thailand Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Vietnam Cancer Diagnostics Market

  • 20.1. Vietnam Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. Malaysia Cancer Diagnostics Market

  • 21.1. Malaysia Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Singapore Cancer Diagnostics Market

  • 22.1. Singapore Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. Philippines Cancer Diagnostics Market

  • 23.1. Philippines Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Hong Kong Cancer Diagnostics Market

  • 24.1. Hong Kong Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. New Zealand Cancer Diagnostics Market

  • 25.1. New Zealand Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Taiwan Cancer Diagnostics Market

  • 26.1. Taiwan Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Taiwan Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. South East Asia Cancer Diagnostics Market

  • 27.1. South East Asia Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 27.2. South East Asia Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. Western Europe Cancer Diagnostics Market

  • 28.1. Western Europe Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. Western Europe Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. UK Cancer Diagnostics Market

  • 29.1. UK Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Germany Cancer Diagnostics Market

  • 30.1. Germany Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. France Cancer Diagnostics Market

  • 31.1. France Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Italy Cancer Diagnostics Market

  • 32.1. Italy Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Spain Cancer Diagnostics Market

  • 33.1. Spain Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Austria Cancer Diagnostics Market

  • 34.1. Austria Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Belgium Cancer Diagnostics Market

  • 35.1. Belgium Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

36. Denmark Cancer Diagnostics Market

  • 36.1. Denmark Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

37. Finland Cancer Diagnostics Market

  • 37.1. Finland Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

38. Ireland Cancer Diagnostics Market

  • 38.1. Ireland Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

39. Netherlands Cancer Diagnostics Market

  • 39.1. Netherlands Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

40. Norway Cancer Diagnostics Market

  • 40.1. Norway Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

41. Portugal Cancer Diagnostics Market

  • 41.1. Portugal Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

42. Sweden Cancer Diagnostics Market

  • 42.1. Sweden Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

42. Switzerland Cancer Diagnostics Market

  • 42.1. Switzerland Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

43. Eastern Europe Cancer Diagnostics Market

  • 43.1. Eastern Europe Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 43.2. Eastern Europe Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

44. Russia Cancer Diagnostics Market

  • 44.1. Russia Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

45. Czech Republic Cancer Diagnostics Market

  • 45.1. Czech Republic Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

46. Poland Cancer Diagnostics Market

  • 46.1. Poland Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

47. Romania Cancer Diagnostics Market

  • 47.1. Romania Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

48. Ukraine Cancer Diagnostics Market

  • 48.1. Ukraine Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

49. North America Cancer Diagnostics Market

  • 49.1. North America Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 49.2. North America Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

50. USA Cancer Diagnostics Market

  • 50.1. USA Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 50.2. USA Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

51. Canada Cancer Diagnostics Market

  • 51.1. Canada Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 51.2. Canada Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

52. Mexico Cancer Diagnostics Market

  • 52.1. Mexico Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 52.2. Mexico Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

53. South America Cancer Diagnostics Market

  • 53.1. South America Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 53.2. South America Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

54. Brazil Cancer Diagnostics Market

  • 54.1. Brazil Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

55. Chile Cancer Diagnostics Market

  • 55.1. Chile Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

56. Argentina Cancer Diagnostics Market

  • 56.1. Argentina Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

57. Colombia Cancer Diagnostics Market

  • 57.1. Colombia Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

58. Peru Cancer Diagnostics Market

  • 58.1. Peru Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

59. Middle East Cancer Diagnostics Market

  • 59.1. Middle East Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 59.2. Middle East Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

60. Saudi Arabia Cancer Diagnostics Market

  • 60.1. Saudi Arabia Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

61. Israel Cancer Diagnostics Market

  • 61.1. Israel Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

62. Iran Cancer Diagnostics Market

  • 62.1. Iran Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

63. Turkey Cancer Diagnostics Market

  • 63.1. Turkey Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

64. United Arab Emirates Cancer Diagnostics Market

  • 64.1. United Arab Emirates Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

65. Africa Cancer Diagnostics Market

  • 65.1. Africa Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 65.2. Africa Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

66. Egypt Cancer Diagnostics Market

  • 66.1. Egypt Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

67. Nigeria Cancer Diagnostics Market

  • 67.1. Nigeria Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

68. South Africa Cancer Diagnostics Market

  • 68.1. South Africa Cancer Diagnostics Market, Segmentation By Products, Segmentation By Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

69. Cancer Diagnostics Market Regulatory and Investment Landscape

70. Cancer Diagnostics Market Competitive Landscape And Company Profiles

  • 70.1. Cancer Diagnostics Market Competitive Landscape And Market Share 2024
    • 70.1.1. Top 10 Companies (Ranked by revenue/share)
  • 70.2. Cancer Diagnostics Market - Company Scoring Matrix
    • 70.2.1. Market Revenues
    • 70.2.2. Product Innovation Score
    • 70.2.3. Brand Recognition
  • 70.3. Cancer Diagnostics Market Company Profiles
    • 70.3.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 70.3.2. Becton Dickinson and Company Overview, Products and Services, Strategy and Financial Analysis
    • 70.3.3. Hologic Overview, Products and Services, Strategy and Financial Analysis
    • 70.3.4. GE Healthcare Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 70.3.5. Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis

71. Cancer Diagnostics Market Other Major And Innovative Companies

  • Siemens Healthcare GmbH, Biogenex Laboratories, Veracyte, PathAI, Bio-Rad Laboratories, BioChain, DiagnoCure, Illumina, Myriad Genetics, CompanionDx, Epic Sciences, Genomic Health, Affymetrix, Agilent Technologies, Adaptive Biotechnologies

72. Global Cancer Diagnostics Market Competitive Benchmarking And Dashboard

73. Key Mergers And Acquisitions In The Cancer Diagnostics Market

74. Cancer Diagnostics Market High Potential Countries, Segments and Strategies

  • 74.1 Cancer Diagnostics Market In 2030 - Countries Offering Most New Opportunities
  • 74.2 Cancer Diagnostics Market In 2030 - Segments Offering Most New Opportunities
  • 74.3 Cancer Diagnostics Market In 2030 - Growth Strategies
    • 74.3.1 Market Trend Based Strategies
    • 74.3.2 Competitor Strategies

75. Appendix

  • 75.1. Abbreviations
  • 75.2. Currencies
  • 75.3. Historic And Forecast Inflation Rates
  • 75.4. Research Inquiries
  • 75.5. The Business Research Company
  • 75.6. Copyright And Disclaimer